Browse By: Country ι Category ι Publisher ι Tag

Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors

Pages » 301
Published By » La Merie Publishing
Price » $2092
In stock
View Report Details
Description

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets: Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) G-CSF & GM-CSF Thrombopoietin & Thrombopoiesis Stimulating Agents Interferon Insulin Coagulation Factors Human Growth Hormone (hGH) FSH, hCG and LH: Therapeutic Pro... Click here for more details


Oncology Pipeline Database: 6-Month Subscription
Oncology Pipeline Database: 6-Month Subscription Product description Subscription to La Merie’s proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and
Published Date: Feb 2010
Price: $1544
Oncology Pipeline Database: 1-Year Subscription
Oncology Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R
Published Date: May 2010
Price: $2316
Flat-Rate Subscription to La Merie Reports with 24/7 Online Access
Subscription to this product provides online access during one year to all reports published by La Merie and available in the online store during the subscription. Among La Merie reports are more than 100 Competitor Analysis reports as well as a growing number of Brief and Full Reports. La Merie r
Published Date: Jun 2010
Price: $5146
R&D Drug Pipeline Database: 1-Year Subscription
R&D Drug Pipeline Database: 1-Year Subscription Product description Subscription to La Meries proprietary R&D Drug Pipeline Database provides online access to more than 12,000 project entries in all therapeutic areas and product categories. Each project is specified for its Target or Mecha
Published Date: Aug 2010
Price: $7719
R&D Drug Pipeline Database: 2-Months Subscription
R&D Drug Pipeline Database: 2-Months Subscription Product description Subscription to La Meries proprietary R&D Drug Pipeline Database provides online access to more than 12,000 project entries in all therapeutic areas and product categories. Each project is specified for its Target or Mec
Published Date: Aug 2010
Price: $2573
Antibody Pipeline Database: 1-Year Subscription
Subscription to La Meries proprietary Antibody Pipeline Database provides online access to more than 1,600 project entries for therapeutic antibodies on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase.
Published Date: Nov 2010
Price: $1544
Therapeutic Protein Pipeline Database: 1-Year Subscription
Subscription to La Merie’s proprietary Therapeutic Protein Pipeline Database provides online access to more than 1,700 project entries for therapeutic proteins on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area a
Published Date: Feb 2011
Price: $1544
RNA Therapeutics Pipeline Database: 1-Year Subscription
RNA Therapeutics Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary RNA Therapeutics Pipeline Database provides online access to RNA Therapeutics on the market and in research & development. RNA Therapeutics include the classes of antisense,
Published Date: Mar 2011
Price: $772
Vaccine Pipeline Database: 1-Year Subscription
Vaccine Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Eac
Published Date: Oct 2011
Price: $1287
Competitor Analysis: Targeted Therapy of Hepatitis C
The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to
Published Date: Aug 2011
Price: $772

 


 

Related News

Brent Crude Oil Prices Rise Above $97 after China: reports PMI
Brent crude experienced a rise of $97 per barrel on Tuesday. This was after a factory in China unexpectedly soared in terms of demand outlook in the global market in September.  The expectations proposed by the analysts for a reading of 50 about Brunt crude oil were beat from 50.2 in August to 50.5 in September as orders continued to rise, reported the HSBC China Purchasing Managers’ Index (PMI).  For November, Brent was up 15 cents by 0646 GMT reaching a value $97.12 per b
Date: Sep 25

Nova Chemicals Corp. Official Shipper for UTOPIA Project
Kinder Morgan Energy Partners recently announced the receiving of its transportation agreement with Nova Chemicals Corp. Nova Chemicals Corp. is headquartered in Alberta, Canada; however holds its operations in Moon Township. The company will receive ethane-propane and ethane mixtures from end to end Utica to Ontario Pipeline Access (UTOPIA) project.  Although more capacity is available within this project, through this deal, the project can advance to higher levels.  Currently,
Date: Sep 30

Innovation Center Established by PepsiCo in Dubai
The world’s food and beverage giant, PepsiCo has recently declared its plan of establishing an innovation center in the life sciences cluster DuBioTech situated in Dubai. This will be PepsiCo’s very first facility in this region. According to PepsiCo, the main rationale of this innovation facility will be to identify and cater to the preferences and tastes of the consumers in the local market. Furthermore, it also aims at promoting innovation in the regional market. In order to en
Date: Sep 30

Bendgate: iPhone 6 Plus Video May Have Been Fake
The YouTube video showing how the new iPhone 6 Plus could be bent out of shape may possibly be a fake. The claim about a ‘bendy’ iPhone 6 Plus went viral across the Internet, earning the name ‘Bendgate’. The video apparently spread panic among Apple users and customers, with them fearing that the smartphone may bend in their trouser pockets. Online forums and social media were abuzz with reactions, with #BendGate trending on Twitter.  Apple Inc. finally broke i
Date: Sep 29

Europeans Accept Chinese Electronics
A research conducted by the consultancy GfK revealed that European markets have grown to be more accepting of Chinese electronics and home appliance brands. The Chinese names have been expanding into European markets recently. The report states the overseas presence of Chinese home appliances and electronics market is increasing and now possesses a matured industry chain and rising shares. Their share will increase considerably once Chinese brands improve quality and performance. Chinese s
Date: Sep 25

News of Hyundai Motor’s Land Bid Sparks Strikes, Makes Wage Talks Complicated
General Motors Co. has announced its plans about opening headquarters of its Cadillac brand in New York next year, as a part of its strategy to expanding the brand’s appeal and remaking its image outside North America. Cadillac’s spokesman David Caldwell stated that the brand’s office, including event space and display, will open in the trendy Manhattan neighborhood Soho. The office is expected to be set up by the second quarter of 2015.  GM has stated that the move
Date: Sep 24

Delphi Takes Over Antaya
Delphi Automotive plc has recently signed an agreement that lets it control Antaya Technologies Corp. Antaya is a leader in providing proprietary on-glass connectors. The move improves Delphi’s portfolio and make it more feasible in the rapidly growing electrical connectors in automotives business. Antaya holds the leading position in the manufacture of on-glass connectors for the North American automotive glass industry. It has a growing customer base in China and Europe. Antaya also p
Date: Sep 23

Indian Regulatory Experts Push for Stronger Pharma Data Integrity
Regulatory experts in India have expressly stated their opinions on adding a special focus on tailing all the data integrity requirements. They are saying that this has to be done to avoid crackdown by regulatory agencies. The warning follows a growing number of letters issued by the US FDA and other international regulatory bodies to the Indian pharmaceutical companies regarding their poor data integrity. Inspectors have discovered major errors in the Indian files. Many firms like Sun Pharma
Date: Sep 22

China’s Huawei to Setup 4G Network in Cambodia
EMAXX, the Cambodian telecommunications company has signed a deal with the Chinese Huawei on Wednesday to build and develop a 4G network in Cambodia. The contract was signed by Ai Minn, the CEO of EMAXX, and the DGM of Huawei Technologies Weng Kefeng. The signing was performed in the presence of the Chinese Embassy’s Cambodian political councilor Li Zhigong and Kan Channmeta, Secretary of State at the Cambodian Ministry of Posts and Telecom. The contract states that Huawei will build
Date: Sep 18

Cost Watchdog of Britain’s Healthcare Sector Approves GSK’s Melanoma Drug under Price-Cut Conditions
Cost control agency of Britain’s healthcare sector, The National Institute for Health and Care Excellence (NICE), has recommended a drug for melanoma marketed by GlaxoSmithKline after the drug maker offered to supply it at a discounted rate to the National Health Service.  The drug, titled Tafinlar, is currently marketed by GSK but it will soon be transferred to Novartis under a trade deal between the tow companies.  Tafinlar is an oral drug that works in a way similar to R
Date: Sep 18

Upcoming Reports

Biopharmaceutical Licensing Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts, 2012 - 2018
The biopharmaceutical industry is focusing on the growing complexity of licensing deals in order to secure marketing and commercialization rights within partnership deals. The major challenge faced by the biopharmaceutical licensing market is asymmetry between licensor and licensees. The biopharma
Published By: Transparency Market Research
Price: $4795
US Biopharmaceutical Market - Global Industry Size, Market Share, Smart Trends, Analysis And Forecast, 2012 - 2018
Biopharmaceuticals are medical drugs which are produced with the help of biotechnology. The US is the largest market for biopharmaceuticals and is the leader in terms of revenue, by a substantial margin. The biopharmaceutical market can be classified based on the class of the medical drug into r
Published By: Transparency Market Research
Price: $4795
Orthopedic Bone Material (Cement and Casting) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
Artificial joints have been anchored with bone cements for more than half a century. Bone cement plays the important role of an elastic zone by filling the space between the prosthesis and the bone. The necessity of bone cement is supported by the fact that the human hip is acted on by 10-12 tim
Published By: Transparency Market Research
Price: $4595
Single-Use Technologies For Biopharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
Single use technologies involve single-use or disposable products. Such products are usually made of plastics or its derivatives such as polyamides, polycarbonates, polyethylene, polyvinyl chloride and various others. These products are becoming popular in the biopharmaceutical applications as the
Published By: Transparency Market Research
Price: $4795